Stock Events

Stock Events

Pasithea Therapeutics 

$0.68
0
-$0.06-7.7% Today

Statistics

Day High
0.69
Day Low
0.65
52W High
-
52W Low
-
Volume
63,023
Avg. Volume
-
Mkt Cap
5.08M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2025
Q4 2025
Next
-0.41
-0.33
-0.26
-0.18
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-27.81MNet Income

Analyst Ratings

$3.00Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KTTA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics develops novel therapies for central nervous system disorders, overlapping with Pasithea's focus.
BridgeBio Pharma
BBIO
Mkt Cap12.07B
BridgeBio Pharma targets genetic diseases and cancers, including neurological disorders, competing with Pasithea's approach.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes plc works on central nervous system diseases, including depression and schizophrenia, areas of interest for Pasithea.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
ACADIA Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, directly competing with Pasithea's focus on mental health and neurological disorders.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's broad focus on innovative therapeutics includes work on central nervous system disorders.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals has a portfolio that includes treatments for psychiatric disorders, competing in Pasithea's market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries offers generic and specialty medicines, including CNS treatments, making it a competitor.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, with its extensive research in neuroscience, competes in developing treatments for disorders targeted by Pasithea.

About

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Show more...
CEO
ISIN
US70261F2020

Listings

BOATS
BOATS
KTTA.BOATS
XNAS
US
KTTAW
XNAS
US
KTTA

0 Comments

Share your thoughts

FAQ

What is Pasithea Therapeutics stock price today?▼
The current price of KTTA.BOATS is $0.68 USD — it has decreased by -7.7% in the past 24 hours. Watch Pasithea Therapeutics stock price performance more closely on the chart.
What is Pasithea Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pasithea Therapeutics stocks are traded under the ticker KTTA.BOATS.
What is Pasithea Therapeutics market cap?▼
Today Pasithea Therapeutics has the market capitalization of 5.08M
When is the next Pasithea Therapeutics earnings date?▼
Pasithea Therapeutics is going to release the next earnings report on June 03, 2026.
What were Pasithea Therapeutics earnings last quarter?▼
KTTA.BOATS earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.18 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pasithea Therapeutics revenue for the last year?▼
Pasithea Therapeutics revenue for the last year amounts to 0 USD.
What is Pasithea Therapeutics net income for the last year?▼
KTTA.BOATS net income for the last year is -27.81M USD.
When did Pasithea Therapeutics complete a stock split?▼
Pasithea Therapeutics has not had any recent stock splits.